Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Frequently asked questions
What sector does NorthView Acquisition Corporation Warrant (NVACW) operate in?
NorthView Acquisition Corporation Warrant belongs to the Financials sector and operates in the industry.
What is NorthView Acquisition Corporation Warrant (NVACW) current stock price?
As of the latest data, NorthView Acquisition Corporation Warrant stock price is $0.11, with a previous close of $0.12. NorthView Acquisition Corporation Warrant lost -$0.01 in the last trading session, representing a -8.33% loss.
What is NorthView Acquisition Corporation Warrant (NVACW) current market capitalization?
NorthView Acquisition Corporation Warrant market cap is approximately 185.69 thousand.
Does NorthView Acquisition Corporation Warrant (NVACW) pay dividends?
No. NorthView Acquisition Corporation Warrant does not pay a dividend.
What is NorthView Acquisition Corporation Warrant (NVACW) beta (volatility) score?
NorthView Acquisition Corporation Warrant has a beta of 0.437, indicating lower volatility than the overall market.